JP2023502005A - インターロイキン－２２の治療用誘導体 - Google Patents

インターロイキン－２２の治療用誘導体 Download PDF

Info

Publication number
JP2023502005A
JP2023502005A JP2022526450A JP2022526450A JP2023502005A JP 2023502005 A JP2023502005 A JP 2023502005A JP 2022526450 A JP2022526450 A JP 2022526450A JP 2022526450 A JP2022526450 A JP 2022526450A JP 2023502005 A JP2023502005 A JP 2023502005A
Authority
JP
Japan
Prior art keywords
derivative
hil
disease
derivatives
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502005A5 (https=
Inventor
クリスティアン・サス－ウルム
ラスムス・ヨルゲンセン
セバスティアン・ベック・ヨルゲンセン
ヘニング・トゥーヤスン
トマス・ホウ－イェンセン
ミカエル・パオロ・バストナー・サンドリニ
Original Assignee
サイトカイ・ファーマ・アーペーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイトカイ・ファーマ・アーペーエス filed Critical サイトカイ・ファーマ・アーペーエス
Publication of JP2023502005A publication Critical patent/JP2023502005A/ja
Priority to JP2023064366A priority Critical patent/JP7479539B2/ja
Publication of JP2023502005A5 publication Critical patent/JP2023502005A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
JP2022526450A 2019-11-07 2020-11-09 インターロイキン－２２の治療用誘導体 Pending JP2023502005A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023064366A JP7479539B2 (ja) 2019-11-07 2023-04-11 インターロイキン－２２の治療用誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19207766.7A EP3819307A1 (en) 2019-11-07 2019-11-07 Therapeutic derivatives of interleukin-22
EP19207766.7 2019-11-07
PCT/EP2020/081523 WO2021089875A1 (en) 2019-11-07 2020-11-09 Therapeutic derivatives of interleukin-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023064366A Division JP7479539B2 (ja) 2019-11-07 2023-04-11 インターロイキン－２２の治療用誘導体

Publications (2)

Publication Number Publication Date
JP2023502005A true JP2023502005A (ja) 2023-01-20
JP2023502005A5 JP2023502005A5 (https=) 2025-02-14

Family

ID=68502950

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022526450A Pending JP2023502005A (ja) 2019-11-07 2020-11-09 インターロイキン－２２の治療用誘導体
JP2023064366A Active JP7479539B2 (ja) 2019-11-07 2023-04-11 インターロイキン－２２の治療用誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023064366A Active JP7479539B2 (ja) 2019-11-07 2023-04-11 インターロイキン－２２の治療用誘導体

Country Status (19)

Country Link
US (5) US11806403B2 (https=)
EP (2) EP3819307A1 (https=)
JP (2) JP2023502005A (https=)
KR (1) KR20220097921A (https=)
CN (2) CN118359699A (https=)
AU (1) AU2020378648A1 (https=)
BR (1) BR112022008497A2 (https=)
CA (1) CA3160338A1 (https=)
CL (1) CL2022001185A1 (https=)
CO (1) CO2022005889A2 (https=)
CR (1) CR20220249A (https=)
GE (2) GEP20257757B (https=)
IL (1) IL292657A (https=)
MX (1) MX2022005547A (https=)
MY (1) MY209488A (https=)
PE (1) PE20221279A1 (https=)
PH (1) PH12022551107A1 (https=)
SA (1) SA522432487B1 (https=)
WO (1) WO2021089875A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3819307A1 (en) 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
WO2021207662A1 (en) * 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
BR112022020796A2 (pt) * 2020-04-17 2022-11-29 Univ Leland Stanford Junior Polipeptídeos de interleucina-22 projetados e usos do mesmos
WO2024133936A2 (en) 2022-12-22 2024-06-27 Cytoki Pharma Aps Dosage regimen for interleukin-22 derivatives
EP4389138A1 (en) 2022-12-22 2024-06-26 Cytoki Pharma ApS Dosage regimen for interleukin-22 derivatives
CN119708194A (zh) * 2023-09-28 2025-03-28 南京诺艾新生物技术有限公司 Il-22突变体及其制备方法与应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013533227A (ja) * 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス Ｆｇｆ２１類似体および誘導体
JP2014501262A (ja) * 2010-12-22 2014-01-20 バクスター・インターナショナル・インコーポレイテッド 水溶性脂肪酸誘導体をタンパク質に抱合させるための材料および方法
JP2016522795A (ja) * 2013-03-15 2016-08-04 ジェネンテック， インコーポレイテッド ＩＬ−２２ポリペプチド及びＩＬ−２２Ｆｃ融合タンパク質並びに使用方法
JP2016531156A (ja) * 2013-09-13 2016-10-06 ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ 修飾された治療剤、及びその組成物
JP2018511574A (ja) * 2015-03-18 2018-04-26 ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ 修飾された治療薬とその組成物
JP7479539B2 (ja) * 2019-11-07 2024-05-08 サイトカイ・ファーマ・アーペーエス インターロイキン－２２の治療用誘導体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR106F (https=) 1964-12-21
CA2718634A1 (en) 2008-03-21 2009-09-24 Wyeth Llc Antibodies against interleukin-10-like cytokines and uses therefor
TW201143790A (en) * 2010-05-13 2011-12-16 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途
CA2878825A1 (en) 2012-07-10 2014-01-16 The Uab Research Foundation Compositions and methods for modulation of il-20 family cytokine activity
US10695406B2 (en) 2014-05-27 2020-06-30 The University Of Queensland Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent
CN106146668A (zh) 2015-04-01 2016-11-23 中国人民解放军第二军医大学 长效白细胞介素22的制备方法及其用途
MX384213B (es) * 2015-07-15 2025-03-14 Protagonist Therapeutics Inc Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
KR20240141853A (ko) * 2017-08-03 2024-09-27 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
CR20200327A (es) 2018-01-26 2020-11-05 Genentech Inc Proteínas de fusión fc il-22 y métodos de uso
BR112022020796A2 (pt) 2020-04-17 2022-11-29 Univ Leland Stanford Junior Polipeptídeos de interleucina-22 projetados e usos do mesmos
EP4089107A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
WO2022238510A1 (en) 2021-05-11 2022-11-17 Cytoki Pharma Aps Therapeutic derivatives of interleukin-22
EP4089108A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013533227A (ja) * 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス Ｆｇｆ２１類似体および誘導体
JP2014501262A (ja) * 2010-12-22 2014-01-20 バクスター・インターナショナル・インコーポレイテッド 水溶性脂肪酸誘導体をタンパク質に抱合させるための材料および方法
JP2016522795A (ja) * 2013-03-15 2016-08-04 ジェネンテック， インコーポレイテッド ＩＬ−２２ポリペプチド及びＩＬ−２２Ｆｃ融合タンパク質並びに使用方法
JP2016531156A (ja) * 2013-09-13 2016-10-06 ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ 修飾された治療剤、及びその組成物
JP2018511574A (ja) * 2015-03-18 2018-04-26 ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ 修飾された治療薬とその組成物
JP7479539B2 (ja) * 2019-11-07 2024-05-08 サイトカイ・ファーマ・アーペーエス インターロイキン－２２の治療用誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ACS MEDICINAL CHEMISTRY LETTERS, vol. 9, JPN6023024901, 2018, pages 577 - 580, ISSN: 0005452615 *

Also Published As

Publication number Publication date
SA522432487B1 (ar) 2024-10-01
PH12022551107A1 (en) 2023-11-20
CN114761422B (zh) 2026-01-02
AU2020378648A1 (en) 2022-06-23
JP7479539B2 (ja) 2024-05-08
US11806403B2 (en) 2023-11-07
WO2021089875A1 (en) 2021-05-14
CO2022005889A2 (es) 2022-07-29
BR112022008497A2 (pt) 2022-07-26
US12447211B2 (en) 2025-10-21
PE20221279A1 (es) 2022-09-05
EP3819307A1 (en) 2021-05-12
GEAP202415970A (en) 2024-12-25
CR20220249A (es) 2022-08-19
US20230381320A1 (en) 2023-11-30
US20240252649A1 (en) 2024-08-01
CA3160338A1 (en) 2021-05-14
MX2022005547A (es) 2022-07-04
GEP20257757B (en) 2025-04-10
EP4055035A1 (en) 2022-09-14
CN118359699A (zh) 2024-07-19
US20220347304A1 (en) 2022-11-03
US20240108731A1 (en) 2024-04-04
MY209488A (en) 2025-07-12
JP2023083380A (ja) 2023-06-15
CL2022001185A1 (es) 2023-02-03
IL292657A (en) 2022-07-01
US20260014257A1 (en) 2026-01-15
US12226487B2 (en) 2025-02-18
CN114761422A (zh) 2022-07-15
KR20220097921A (ko) 2022-07-08

Similar Documents

Publication Publication Date Title
JP7479539B2 (ja) インターロイキン－２２の治療用誘導体
EP1121155B1 (en) Site-directed dual pegylation of proteins
DK2875043T3 (en) glucagon
JP2012067100A (ja) Ｉｌ−２１の誘導体
KR20150021087A (ko) 페길화된 옥신토모둘린 변이체
US20240279297A1 (en) Therapeutic derivatives of interleukin-22
EP4089107A1 (en) Therapeutic derivatives of interleukin-22
CN117616035A (zh) 白介素-22的治疗性衍生物
JP2007533298A (ja) Ｉｌ−２１の誘導体
TW202140074A (zh) Fgf-21結合物調配物
US20230310630A1 (en) Therapeutic use of combination comprising triple agonistic long-acting conjugate or triple agonist
EA049770B1 (ru) Терапевтические производные интерлейкина-22
HK40108760A (zh) 白细胞介素-22的治疗性衍生物
US20250360186A1 (en) Dosage regimen for interleukin-22 derivatives
US20240002467A1 (en) Compositions and methods of inhibiting the binding of plasma igg autoantibodies to serotonin 2a receptor

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250520